newsfilter
← Latest News
Business Wire·

Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting

– Company Presents Poster on Overall Survival and Long-Term Safety Results from INTRIGUE Study; Second Poster Presents Analysis from INTRIGUE Patients without Detectable ctDNA at Baseline – – Encore Oral Presentation